Summary
Compiles FDA Project Optimus requirements, dose-finding trial precedents, and CDER review expectations to support oncology dose optimization strategies.
Detailed Description
The Dose Optimization Pack addresses the FDA's Project Optimus initiative, which fundamentally shifts the paradigm away from maximum tolerated dose toward optimized dosing in oncology. This pack aggregates the latest FDA guidance, CDER review precedents, and published dose-finding trial data to help sponsors design compliant and scientifically sound dose optimization strategies.
It analyzes historical oncology dose-finding trials, including randomized dose-comparison studies, to benchmark design approaches that have met FDA expectations. The pack identifies common deficiencies cited in FDA review documents and information requests related to dose selection.
Deliverables include a dose optimization strategy document aligned with Project Optimus principles, a gap analysis comparing your planned approach to FDA expectations, and a summary of precedent dose-comparison trials with their regulatory outcomes.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| FDA Project Optimus Guidance | REGULATORY | FDA guidance and communications on optimizing dosing strategies for oncology drugs | Monthly |
| Oncology Dose-Finding Trials | REGISTRY | Database of dose-finding and dose-comparison oncology trials from ClinicalTrials.gov with outcomes | Weekly |
| CDER Review Documents | REGULATORY | FDA multi-discipline review documents and information requests related to oncology dose selection | Monthly |
Regulatory Mapping
Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases
Dose-Response Information to Support Drug Registration
Project Optimus: Reforming the Dose Optimization and Dose Selection Paradigm in Oncology
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
Dose Optimization Strategy Brief
PDFComprehensive strategy document aligned with Project Optimus principles including study design recommendations
Regulatory Gap Analysis
PDFGap analysis comparing planned dose selection approach to FDA expectations with remediation recommendations
Dose-Finding Precedent Table
XLSXStructured comparison of precedent dose-comparison trials with regulatory outcomes and design features
Deliverables included
- Project Optimus compliance assessment
- Dose optimization strategy aligned with FDA expectations
- Precedent analysis of randomized dose-comparison trials
- Dose-exposure-response modeling recommendations
- Post-marketing dose optimization commitment framework
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Solid Tumors | Non-Small Cell Lung Cancer | EGFRALKPD-L1KRAS G12C | Primary |
| Solid Tumors | Breast Cancer | HER2ER/PRBRCA1/2PIK3CA | Primary |
| Hematologic Malignancies | Acute Myeloid Leukemia | FLT3-ITDIDH1/2NPM1 | Secondary |
| Solid Tumors | Colorectal Cancer | KRAS/NRASBRAF V600EMSI-H/dMMR | Secondary |
Related Packs in Oncology
Oncology Trial Design Pack
Design smarter trials with real-world precedent data
Biomarker-Driven Trial Design Pack
Turn molecular insights into registration-ready trial designs
Immuno-Oncology Combination Pack
Build the regulatory case for your IO combination
Accelerated Approval Evidence Pack
Build a bulletproof accelerated approval submission
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.